Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Erica L. Mayer, MD, MPH, on Palbociclib Plus Endocrine Therapy in HR+/HER2– Breast Cancer

Posted: Wednesday, October 28, 2020

Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, discusses findings from the PALLAS study on palbociclib plus endocrine therapy, a first-line regimen that benefits patients with metastatic breast cancer. To date, the trial has not shown benefit in the adjuvant setting, but PALLAS researchers continue to examine tumor tissue and blood samples to see whether a subgroup will emerge for whom CDK4/6 inhibition could be helpful.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.